455 related articles for article (PubMed ID: 33322519)
1. CA125 and Ovarian Cancer: A Comprehensive Review.
Charkhchi P; Cybulski C; Gronwald J; Wong FO; Narod SA; Akbari MR
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33322519
[TBL] [Abstract][Full Text] [Related]
2. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
3. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
4. Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study.
Feng LY; Liao SB; Li L
J Ovarian Res; 2020 Feb; 13(1):17. PubMed ID: 32050995
[TBL] [Abstract][Full Text] [Related]
5. Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer.
Guo J; Yang WL; Pak D; Celestino J; Lu KH; Ning J; Lokshin AE; Cheng Z; Lu Z; Bast RC
Cancers (Basel); 2019 Apr; 11(5):. PubMed ID: 31035430
[TBL] [Abstract][Full Text] [Related]
6. Subtypes of Ovarian Cancer and Ovarian Cancer Screening.
Koshiyama M; Matsumura N; Konishi I
Diagnostics (Basel); 2017 Mar; 7(1):. PubMed ID: 28257098
[TBL] [Abstract][Full Text] [Related]
7. Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.
Skates SJ; Greene MH; Buys SS; Mai PL; Brown P; Piedmonte M; Rodriguez G; Schorge JO; Sherman M; Daly MB; Rutherford T; Brewster WR; O'Malley DM; Partridge E; Boggess J; Drescher CW; Isaacs C; Berchuck A; Domchek S; Davidson SA; Edwards R; Elg SA; Wakeley K; Phillips KA; Armstrong D; Horowitz I; Fabian CJ; Walker J; Sluss PM; Welch W; Minasian L; Horick NK; Kasten CH; Nayfield S; Alberts D; Finkelstein DM; Lu KH
Clin Cancer Res; 2017 Jul; 23(14):3628-3637. PubMed ID: 28143870
[No Abstract] [Full Text] [Related]
8. Efficacy of HE4, CA125, Risk of Malignancy Index and Risk of Ovarian Malignancy Index to Detect Ovarian Cancer in Women with Presumed Benign Ovarian Tumours: A Prospective, Multicentre Trial.
Dochez V; Randet M; Renaudeau C; Dimet J; Le Thuaut A; Winer N; Thubert T; Vaucel E; Caillon H; Ducarme G
J Clin Med; 2019 Oct; 8(11):. PubMed ID: 31699959
[TBL] [Abstract][Full Text] [Related]
9. Borderline ovarian tumours: retrospective analysis of twenty-one cases.
Saygili U; Uslu T; Erten O; Doğan E
Eur J Gynaecol Oncol; 1998; 19(2):182-5. PubMed ID: 9611063
[TBL] [Abstract][Full Text] [Related]
10. Better Predictive Value of Cancer Antigen125 (CA125) as Biomarker in Ovary and Breast Tumors and its Correlation with the Histopathological Type/Grade of the Disease.
Nazmeen A; Maiti S; Mandal K; Roy SK; Ghosh TK; Sinha NK; Mandal K
Med Chem; 2017; 13(8):796-804. PubMed ID: 28440189
[TBL] [Abstract][Full Text] [Related]
11. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer.
Olivier RI; Lubsen-Brandsma MA; Verhoef S; van Beurden M
Gynecol Oncol; 2006 Jan; 100(1):20-6. PubMed ID: 16188302
[TBL] [Abstract][Full Text] [Related]
12. The Potential Role of MUC16 (CA125) Biomarker in Lung Cancer: A Magic Biomarker but with Adversity.
Saad HM; Tourky GF; Al-Kuraishy HM; Al-Gareeb AI; Khattab AM; Elmasry SA; Alsayegh AA; Hakami ZH; Alsulimani A; Sabatier JM; Eid MW; Shaheen HM; Mohammed AA; Batiha GE; De Waard M
Diagnostics (Basel); 2022 Nov; 12(12):. PubMed ID: 36552994
[TBL] [Abstract][Full Text] [Related]
13. A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer.
Salminen L; Nadeem N; Jain S; Grènman S; Carpén O; Hietanen S; Oksa S; Lamminmäki U; Pettersson K; Gidwani K; Huhtinen K; Hynninen J
Gynecol Oncol; 2020 Mar; 156(3):689-694. PubMed ID: 31889528
[TBL] [Abstract][Full Text] [Related]
14. CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer.
Memarzadeh S; Lee SB; Berek JS; Farias-Eisner R
Int J Gynecol Cancer; 2003; 13(2):120-4. PubMed ID: 12657110
[TBL] [Abstract][Full Text] [Related]
15. Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer.
Arits AH; Stoot JE; Botterweck AA; Roumen FJ; Voogd AC
Int J Gynecol Cancer; 2008; 18(4):621-8. PubMed ID: 17868339
[TBL] [Abstract][Full Text] [Related]
16. Clinical application of HE4 and CA125 in ovarian cancer type I and type II detection and differential diagnosis.
Gąsiorowska E; Michalak M; Warchoł W; Lemańska A; Jasiński P; Spaczyński M; Nowak-Markwitz E
Ginekol Pol; 2015 Feb; 86(2):88-93. PubMed ID: 25807831
[TBL] [Abstract][Full Text] [Related]
17. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
18. Preoperative tumor marker CA125 levels in relation to epithelial ovarian cancer stage.
Fures R; Buković D; Hodek B; Klarić B; Herman R; Grubisić G
Coll Antropol; 1999 Jun; 23(1):189-94. PubMed ID: 10402722
[TBL] [Abstract][Full Text] [Related]
19. Personalizing CA125 levels for ovarian cancer screening.
Dorigo O; Berek JS
Cancer Prev Res (Phila); 2011 Sep; 4(9):1356-9. PubMed ID: 21893498
[TBL] [Abstract][Full Text] [Related]
20. Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer.
Zwakman N; van de Laar R; Van Gorp T; Zusterzeel PL; Snijders MP; Ferreira I; Massuger LF; Kruitwagen RF
J Gynecol Oncol; 2017 Jan; 28(1):e7. PubMed ID: 27670261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]